Hong Kong, 24 June 2022 – EuroEyes International Eye Clinic Limited (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846), a leading global vision correction service provider, announced that today it has distributed the final dividend for the year ended 31 December 2021 to its shareholders.
The final dividend paid was HK$0.09932 per ordinary share, which is equivalent to a dividend payout ratio of 25% of net profit after tax (NPAT). This compares to a HK$0.02988 per ordinary share and dividend payout ratio of 15% of NPAT in the previous year, further demonstrating the continued growth and profitability of EuroEyes, and its commitment to providing shareholder value year after year.
With the share price of the Company at HK$6.83 at market close on 24 June 2022, the annualised dividend yield is 1.5%, and profit rate per share was 5.8%.
Dr. Jørn Slot Jørgensen, Founder, Chairman and CEO of EuroEyes, said: “We had an exceptional year in 2021 with revenue growth of 33.6% to approximately HK$632.9 million and adjusted NPAT grew 94.4% to approximately HK$137.3 million, taking our adjusted NPAT margin to 21.7%. We were able to achieve such great financial results – the best year so far – all through organic growth of the business, despite an ongoing pandemic that has impacted many businesses around the world. This underscores the relevance of our service and the strong recognition of the EuroEyes brand amongst our clients, and we aim to remain the top clinic of choice for vision correction, particularly as we further expand our presence in key growth markets such as China and the United Kingdom.”
In March 2022, EuroEyes opened its Chengdu clinic, the eighth clinic in Mainland China, and a new flagship clinic in Copenhagen. In January 2022, the company announced it has entered into a Share Purchase Agreement to acquire London Vision Clinic Partners Limited in the United Kingdom, further expanding its footprint in Europe’s high-end vision correction market. This brings the total number of EuroEyes clinics around the world to 29.
Earlier this month, the Group has appointed two world leading ophthalmologists to its International Medical Advisory Board, which advises the company on breakthroughs in treatment, technology and overall trends in cataract and refractive surgeries that would advance EuroEyes’ leadership in vision correction.
EuroEyes will continue to capitalise on the growing demand for vision correction, and identify new clinic locations or optimise existing surgical centres to better serve clients and achieve greater business results for shareholders.
About EuroEyes International Eye Clinic Limited
EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualised customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark and the PRC. The Group's vision correction services include (i) refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation).
For more information, please visit www.euroeyes.hk.
Hume Brophy Communications:
Ashley So, Jane Hung, Connie Chan – email@example.com